Acute Leukemia : Update of Clinical Aspects
Acute Leukemia : Update of Clinical Aspects
复制标题
DOI：
--
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
H. Tamai;K. Inokuchi
中科院分区：
文献类型：
--
作者：
H. Tamai;K. Inokuchi
位于11 q23的MLL基因重排是与急性白血病（AL）相关的常见染色体异常，特别是婴儿和先前用DNA拓扑异构酶II抑制剂治疗后的继发性白血病。11 q23/MLL异常已被广泛认为是AL的一个重要预后因素。迄今为止，已鉴定出70多个11 q23染色体伴侣，其中至少50个已被克隆并在分子水平上进行了表征。最近的研究表明，11 q23/MLL AL的预后根据伴侣基因、白血病细胞谱系、患者年龄和给予的治疗而变化很大。根据融合伙伴的说法，治疗11 q23/MLL AL需要特殊的策略，包括异基因造血干细胞移植。为了改善11 q23/MLL AL的预后，还需要开发新的方法，包括新的分子治疗靶点。本文根据融合伴侣对11 q23/MLL AL的预后和治疗现状进行了更新。（临床实验血液病理学杂志50（2）：91-98，2010）
Rearrangements of the MLL gene located at 11q23 are common chromosomal abnormalities associated with acute leukemia (AL), especially infant and secondary leukemia after previous treatment with DNA topoisomerase II inhibitors. 11q23/MLL abnormalities have been widely recognized as an important prognostic factor in AL. Over 70 chromosome partners of 11q23 have been identified to date, at least 50 of which have been cloned and characterized at the molecular level. Recent studies showed that the prognosis of 11q23/MLL AL varies widely according to the partner gene, the leukemia cell lineage, the age of the patient and the treatment administered. Special strategies are needed to treat 11q23/MLL AL, including allogeneic hematopoietic stem cell transplantation, according to the fusion partner. The development of novel methodologies, including new molecular therapeutic targets, is also needed to improve the prognosis of 11q23/MLL AL. The present article provides an update on the current status of prognosis and treatment of 11q23/MLL AL according to the fusion partner. 〔J Clin Exp Hematopathol 50(2) : 91-98, 2010〕